Biotech

All Articles

Analysts explore Avidity's DMD win, disclosing nuances in information

.Avidity Biosciences pleased investors along with period 1/2 data in Duchenne muscular dystrophy (DM...

Actinogen's cortisol blocker neglects phase 2 anxiety study

.Actinogen Medical's cortisol blocker has skipped the key endpoint of a period 2 study in anxiety, l...

Bivictrix determines going private only technique to take ADC right into medical clinic

.Antibody-drug conjugates (ADCs) have been at the center of several a billion-dollar biobuck licensi...

TPG tops up funds to $580M for investments around life scientific researches

.Resource manager TPG, which has assisted biotechs including Sionna Therapies and Santa Clam Ana Bio...

Merck quits period 3 TIGIT test in bronchi cancer cells for futility

.Merck &amp Co.'s TIGIT system has actually endured yet another problem. Months after shuttering a s...

After a tough year, Exscientia folds right into Recursion

.After a year described by pipe hairstyles, the departure of its CEO and discharges, Exscientia will...

Cullinan, after $25M bargain, return bispecific to Harbour

.Cullinan Therapeutics was blown away enough with Harbour BioMed's bispecific immune activator that ...

A deeper look at Fierce Biotech's Intense 15

.In this week's incident of "The Best Pipe," we're diving in to Intense Biotech's yearly Brutal 15 e...

Lilly experiences phase 2 breakdown of tau-targeting med

.The confetti is still flying from Eli Lilly's event commemorating the commendation of Alzheimer's d...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Invite to today's Chutes &amp Ladders, our summary of significant leadership hirings, shootings and...